Evaluating the Impact of Different Natural History Modeling Methods on Cost-Effectiveness Decisions: A Case Study in Duchenne Muscular Dystrophy
MDM Policy & Practice · 2026-01 · 11 (1)
DOI: 10.1177/23814683261447231 ↗Kurz gefasst
Fachartikel in der Zeitschrift MDM Policy & Practice, online erschienen am 11.06.2026. Verfasst von Jonathan Broomfield und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics Research Group, Department of Population Health Sciences, University of Leicester, Leicester, UK. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Cost-effectiveness analyses are vital in guiding decisions on treatment reimbursement. Natural history models are central to these, enabling the estimation of long-term costs and quality-adjusted life-years (QALYs) in the absence of lifetime trial data. Rare disease data are often scarce, resulting in disease progression being estimated through clinical assumptions. This study aims to evaluate how different modeling approaches influence cost-effectiveness estimates in rare disease health technology assessments (HTAs), using Duchenne muscular dystrophy (DMD) as a case study.
Methods
A published economic model was used to compare 2 approaches for estimating disease progression: an assumption-based method relying on clinical plausibility and data-driven methods using data from 1,005 patients with DMD across 8 studies. Transition probabilities were estimated assuming increasing flexibility of study heterogeneity and compared with a simulated treatment cohort. Models were evaluated by comparing incremental cost-effectiveness ratios (ICERs) across approaches. No gold standard exists, so the plausibility of predictions was evaluated by comparing survival and disease progression estimates to published milestones.
Results
Results showed that although the assumption-based model was clinically plausible, it predicted higher QALY gains (0.77) and lower ICERs (£1.96M per QALY) than data-driven methods did, which estimated QALY gains of 0.25, 0.26, 0.27, and 0.28 and ICERs of £6.2M, £6.2M, £5.8M, and £5.7M per QALY for the least to most flexible models, respectively.
Limitations
No covariate effects or updated cost and utility data were incorporated, as the study purpose was a methodological comparison between approaches. Analyses were deterministic not probabilistic. Conclusions and Implications. This study emphasizes the critical role of model selection for HTA in rare diseases, showing that cost-effectiveness estimates from robust data-driven approaches can differ from clinically plausible assumption-based models. Highlights The choice of a natural history modeling method can drastically alter the cost-effectiveness results in rare disease evaluations. A case study in Duchenne muscular dystrophy demonstrates how different modeling approaches yield divergent cost-effectiveness outcomes. Assumption-based models, even when clinically plausible, may underestimate measures of cost-effectiveness and result in less reliable guidance for decision makers. Data-driven models using real-world patient data provide more reliable estimates for health technology assessment (HTA). This study offers practical guidance for analysts and HTA bodies on selecting robust modeling approaches in rare disease contexts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biostatistics Research Group, Department of Population Health Sciences, University of Leicester, Leicester, UK.
- Department of Respiratory Sciences, University of Leicester, Leicester, UK.
- Department of Statistics & Warwick Medical School, University of Warwick, Coventry, UK.
- Centre for Health Economics, University of York, York, UK.
- Red Door Analytics, Stockholm, Sweden.
- John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle, UK.
ORCID-Profile: Jonathan Broomfield, Michael J Crowther
Zitieren
APA
Broomfield, J., Abrams, K. R., Crowther, M. J., Guglieri, M., Latimer, N. R., & Rutherford, M. J. (2026). Evaluating the Impact of Different Natural History Modeling Methods on Cost-Effectiveness Decisions: A Case Study in Duchenne Muscular Dystrophy. MDM Policy & Practice, 11(1). https://doi.org/10.1177/23814683261447231
Vancouver
Broomfield J, Abrams KR, Crowther MJ, Guglieri M, Latimer NR, Rutherford MJ. Evaluating the Impact of Different Natural History Modeling Methods on Cost-Effectiveness Decisions: A Case Study in Duchenne Muscular Dystrophy. MDM Policy & Practice. 2026;11(1). doi:10.1177/23814683261447231
BibTeX
@article{Broomfield2026,
author = {Broomfield, Jonathan and Abrams, Keith R and Crowther, Michael J and Guglieri, Michela and Latimer, Nicholas R and Rutherford, Mark J},
title = {Evaluating the Impact of Different Natural History Modeling Methods on Cost-Effectiveness Decisions: A Case Study in Duchenne Muscular Dystrophy},
journal = {MDM Policy & Practice},
year = {2026},
volume = {11},
number = {1},
doi = {10.1177/23814683261447231}
}
EUVIMED